Catherine M. Szyman - Aug 9, 2023 Form 4 Insider Report for Edwards Lifesciences Corp (EW)

Role: CVP, Critical Care
Signature: Linda J. Park, Attorney-in-Fact
Stock symbol: EW
Transactions as of: Aug 9, 2023
Transactions value $: -$209,435
Form type: 4
Date filed: 8/9/2023, 05:44 PM
Previous filing: Jul 10, 2023
Next filing: Sep 8, 2023

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	EW	Common Stock	Options Exercise	$184K	+5K	+14.36%	$36.75	39.8K	Aug 9, 2023	Direct	F1
transaction	EW	Common Stock	Sale	-$393K	-5K	-12.56%	$78.64	34.8K	Aug 9, 2023	Direct	F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	EW	Employee Stock Option (Right to Acquire)	Options Exercise	$0	-5K	-8.06%	$0.00	57K	Aug 9, 2023	Common Stock	5K	$36.75	Direct

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id	Content
F1	The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 6, 2023.
F2	This transaction was executed in multiple trades at prices ranging from $78.44 to $78.95. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.

Remarks:

This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the reporting person.